ECSP14013269A - Forma de dosificación resistente a la alteración comprendiendo agonista opioide y antagonista opioide - Google Patents

Forma de dosificación resistente a la alteración comprendiendo agonista opioide y antagonista opioide

Info

Publication number
ECSP14013269A
ECSP14013269A ECSP14013269A ECSP14013269A EC SP14013269 A ECSP14013269 A EC SP14013269A EC SP14013269 A ECSP14013269 A EC SP14013269A EC SP14013269 A ECSP14013269 A EC SP14013269A
Authority
EC
Ecuador
Prior art keywords
opioid
dosage form
alteration
understanding
opioid antagonist
Prior art date
Application number
Other languages
English (en)
Inventor
Lutz Barnscheid
Anja Geissler
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018994&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of ECSP14013269A publication Critical patent/ECSP14013269A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una forma de dosificación farmacéutica para administración oral que tiene una resistencia a rompimiento de al menos 300 N y que comprende un agonista opioide, un antagonista opioide, y un óxido de polialquileno que tiene un peso molecular promedio de al menos 200,000 g/mol, en donde de acuerdo con Ph. Eur. el perfil de liberación in vitro del agonista opioide esencialmente corresponde al perfil de liberación in vitro del antagonista opioide, y en donde el agonista opioide y el antagonista opioide se mezclan íntimamente entre sí y se mezclan de manera homogénea en el óxido de polialquileno.
ECSP14013269 2011-10-06 2014-03-25 Forma de dosificación resistente a la alteración comprendiendo agonista opioide y antagonista opioide ECSP14013269A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11008131 2011-10-06
EP11009090 2011-11-16
EP12001297 2012-02-28

Publications (1)

Publication Number Publication Date
ECSP14013269A true ECSP14013269A (es) 2014-12-30

Family

ID=47018994

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013269 ECSP14013269A (es) 2011-10-06 2014-03-25 Forma de dosificación resistente a la alteración comprendiendo agonista opioide y antagonista opioide

Country Status (18)

Country Link
US (1) US20130090349A1 (es)
EP (1) EP2763664A2 (es)
JP (1) JP2014528437A (es)
KR (1) KR20140075704A (es)
CN (1) CN103998025A (es)
AR (1) AR088250A1 (es)
AU (1) AU2012320496C1 (es)
BR (1) BR112014008120A2 (es)
CA (1) CA2850853A1 (es)
CL (1) CL2014000361A1 (es)
CO (1) CO6950467A2 (es)
EA (1) EA029508B1 (es)
EC (1) ECSP14013269A (es)
HK (1) HK1200741A1 (es)
IL (1) IL230819A0 (es)
MX (1) MX2014003973A (es)
PE (1) PE20141171A1 (es)
WO (1) WO2013050539A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
BR112012001466A2 (pt) * 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
KR20140096062A (ko) * 2011-11-17 2014-08-04 그뤼넨탈 게엠베하 약리학적 활성 성분, 오피오이드 길항제 및/또는 혐오제, 폴리알킬렌 옥사이드 및 음이온성 중합체를 포함하는 탬퍼-저항성 경구 약제학적 투여형
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
AU2014273227B2 (en) * 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
JP6232135B2 (ja) 2013-11-13 2017-11-15 ユーロ−セルティーク エス．エイ． 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
US10105360B2 (en) 2013-12-11 2018-10-23 Develco Pharma Schweiz Ag Method and composition for the treatment of opioid induced constipation
US9456986B2 (en) 2013-12-11 2016-10-04 Develco Pharma Schweiz Ag Naloxone mono preparation and multilayer tablet
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3086789A4 (en) * 2013-12-23 2017-08-02 Purdue Pharma L.P. Opioid antagonist formulations
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
BR112017022856A2 (pt) 2015-04-24 2018-07-17 Gruenenthal Gmbh combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
WO2016170093A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix
US20160310428A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
EP3290027A1 (en) * 2016-09-02 2018-03-07 Develco Pharma Schweiz AG Method and composition for the treatment of opioid induced constipation
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
US12161754B2 (en) 2017-12-20 2024-12-10 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
CA3195386A1 (en) * 2020-10-16 2022-04-21 Qi Fang Controlled release fill compositions and capsules containing same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19710008A1 (de) * 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
AU2002321879A1 (en) 2001-08-06 2003-03-03 Thomas Gruber Pharmaceutical formulation containing dye
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
LT2425821T (lt) * 2002-04-05 2017-07-25 Euro-Celtique S.A. Farmacinis preparatas, turintis oksikodono ir naloksono
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
PL1740156T3 (pl) 2004-04-22 2011-12-30 Gruenenthal Gmbh Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
PL1765298T3 (pl) 2004-07-01 2013-01-31 Gruenenthal Gmbh Sposób wytwarzania stałej postaci dawkowania, która jest zabezpieczona przez nadużywaniem, wykorzystujący wytłaczarkę z przekładnią planetarną
CA2572491A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
AR053304A1 (es) 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
BRPI0513608A (pt) * 2004-07-27 2008-05-13 Unilever Nv composição para o cuidado dos cabelos, processo para a preparação de uma composição para o cuidado dos cabelos e método para o tratamento dos cabelos
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20060194759A1 (en) * 2005-02-25 2006-08-31 Eidelson Stewart G Topical compositions and methods for treating pain and inflammation
RU2433817C2 (ru) * 2006-01-21 2011-11-20 Эбботт Гмбх Унд Ко.Кг Лекарственная форма и способ для доставки вызывающих зависимость лекарственных веществ
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
HUE028066T2 (en) 2008-07-31 2016-11-28 Anglo Netherlands Grain Bv Herbicide-resistant sunflower plants
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
BR112012001466A2 (pt) * 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem

Also Published As

Publication number Publication date
EA029508B1 (ru) 2018-04-30
EP2763664A2 (en) 2014-08-13
NZ620252A (en) 2015-09-25
KR20140075704A (ko) 2014-06-19
WO2013050539A2 (en) 2013-04-11
US20130090349A1 (en) 2013-04-11
AU2012320496B2 (en) 2017-05-18
CL2014000361A1 (es) 2014-06-20
CA2850853A1 (en) 2013-04-11
AU2012320496A1 (en) 2014-02-13
IL230819A0 (en) 2014-03-31
JP2014528437A (ja) 2014-10-27
AU2012320496C1 (en) 2017-09-28
CO6950467A2 (es) 2014-05-20
AR088250A1 (es) 2014-05-21
WO2013050539A3 (en) 2013-05-30
PE20141171A1 (es) 2014-09-21
BR112014008120A2 (pt) 2017-04-11
MX2014003973A (es) 2014-05-07
EA201400413A1 (ru) 2014-11-28
CN103998025A (zh) 2014-08-20
HK1200741A1 (en) 2015-08-14

Similar Documents

Publication Publication Date Title
MX2014003973A (es) Forma de dosificacion farmaceutica oral resistente a alteracion comprendiendo agonista opioide y antagonista opioide.
CO7210299A2 (es) Forma de dosis farmaceútica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico
ECSP22034515A (es) FORMULACIONES PARA ANTICUERPOS ANTI Alfa4Beta7
MX2015016254A (es) Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
CL2011002969A1 (es) Forma de dosificacion termoformada que presenta una resistencia a la rotura de 300 n que comprende un opioide, 0,001 y 5,0 % de una acido y un oxido de polialquelino con peso molecular de al menos 500.000 g/mol; empaquetamiento que la comprende junto a un secuestrador de oxigeno.
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CY1117479T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
NZ709958A (en) Enhanced stability of novel liquid compositions
BRPI0905717A2 (pt) Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica
CL2017002682A1 (es) Forma de dosificación resistente a alteraciones con liberación inmediata y resistencia contra la extracción por solventes
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
ECSP13012411A (es) Composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona
EA201290116A1 (ru) Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
ES2415029R1 (es) Composición farmacéutica y método para inhibir la producción o amplificar la eliminación de la proteína P24.
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
GT201400042A (es) Compuesto de benzotiazolona
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
EA201391643A1 (ru) Составы с замедленным высвобождением парацетамола
BR112013011763A2 (pt) composição farmacêutica e forma galênica à base de dronedarona e o respectivo processo de preparo
MX2012013178A (es) Composicion antiparasitaria de amplio espectro de nitazoxanida, probioticos y prebioticos.
CY1119701T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει υδροχλωρικη βαρδεναφιλη
ECSP12012088A (es) Composición farmacéutica sólida para administración bucal de agomelatina
ECSP14000928A (es) Forma de dósis farmacéutica oral a prueba de manipulación que comprende un agente antagonista y/o repelente opioide, óxido de polialquileno y un polímero aniónico